News from daiichi sankyo, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

May 16, 2014, 07:33 ET

Journée Mondiale de l'Hypertension 2014 : Daiichi Sankyo fait du bien à votre cœur !

  - La Journée Mondiale de l'Hypertension a lieu chaque année le 17 mai. Le thème choisi pour 2014 est "Connaître...

May 15, 2014, 09:54 ET

Giornata Mondiale contro l'Ipertensione Arteriosa 2014

Daiichi Sankyo e "Little Hearts" insieme per gli orfani dell'Est Europa  Il 17 maggio ricorre la decima edizione della Giornata Mondiale...

May 15, 2014, 08:50 ET

Daiichi Sankyo pone en marcha la iniciativa "Haz que tu corazón se sienta bien"

Daiichi Sankyo pone en marcha la iniciativa "Haz que tu corazón se sienta bien" -...

Apr 18, 2014, 09:00 ET

Ken Keller Named President, US Commercial, Daiichi Sankyo, Inc.

 Daiichi Sankyo, Inc. announced today that Ken Keller will join the company as President of its Commercial operations in the United States...

Apr 02, 2014, 07:00 ET

Daiichi Sankyo extends the PREFER in AF patient registry to provide additional insights into the long-term management of patients with atrial fibrillation

For European Media Only, Not for UK Media   Atrial fibrillation (AF) is the most common heart rhythm disorder[1] resulting in a...

Mar 31, 2014, 07:00 ET

Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has started enrolling patients into the ENSURE-AF multinational...

Mar 24, 2014, 07:00 ET

Once-Daily Edoxaban Evaluated in Two Subgroup Analyses of East Asian Patients from the Largest Comparative Phase 3 Trials of a Novel Oral Anticoagulant

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced late-breaking data from two pre-specified subgroup analyses of...

Jan 08, 2014, 12:29 ET
Jan 08, 2014, 08:30 ET

Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics

Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly...

Jan 07, 2014, 11:09 ET
Dec 19, 2013, 07:04 ET

Daiichi Sankyo Submits Supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for New Indications

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its...

Dec 09, 2013, 08:05 ET

Phase 3 Data Show Daiichi Sankyo's Once-Daily Edoxaban Lowered Incidence of VTE Recurrence and Clinically Relevant Bleeding Compared to Warfarin in a Large Subgroup of Patients with Cancer

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients...

Nov 19, 2013, 11:50 ET
Oct 03, 2013, 16:00 ET

Daiichi Sankyo, Inc. Makes Two New Executive Appointments

 Daiichi Sankyo, Inc. today announced that Glenn Gormley, MD, PhD, has been named corporate President and Chairman of Daiichi Sankyo, Inc....

Sep 01, 2013, 02:15 ET
Jul 29, 2013, 00:00 ET

Daiichi Sankyo va élargir à l'Allemagne, la Suisse et l'Autriche son programme collaboratif de découverte de médicaments

Daiichi Sankyo Company, Limited (ci-après dénommée Daiichi Sankyo) a annoncé le 29 juillet qu'elle va élargir son...

Jul 29, 2013, 00:00 ET

Daiichi Sankyo erweitert sein gemeinsames Arzneimittelforschungsprogramm auf Deutschland, die Schweiz und Österreich

Daiichi Sankyo Company, Limited (nachfolgend Daiichi Sankyo genannt) gab am 29. Juli bekannt, dass das Unternehmen sein gemeinsames...

Jun 25, 2013, 04:25 ET

23º Congreso de la Sociedad Europea de Hipertensión - ESH 2013

El estudio SEVITENSION demuestra la superioridad de Sevikar® (olmesartán y amlodipino) frente a la combinación de perindopril...

Jun 25, 2013, 04:25 ET

23ème congrès européen sur l'Hypertension et la Protection Cardiovasculaire

De nouvelles données de l'étude SEVITENSION montrent la supériorité de l'association à doses fixes Sevikar®...

Jun 25, 2013, 04:25 ET

Congresso ESH 2013, dallo studio SEVITENSION nuove evidenze sull'efficacia della combinazione fissa olmesartan/amlodipina vs. perindopril/amlodipina nel controllo della pressione arteriosa centrale

Nel corso del 23° Congresso della Società Europea di Ipertensione sono stati presentati gli ultimi dati dello studio SEVITENSION, che...

Organizations in the News

The organizations with the most activity in PR Newswire's News Room

ReportBuyer
Research and Markets
Investor-Edge